ImmPACT Bio

CAR-T Cell Therapies for Treating Cancer

Startup

ImmPACT Bio is a Rehovot-based startup in the Health Tech & Life Sciences sector, established in 2017. CAR-T Cell Therapies for Treating Cancer. The company has raised a total of $137M across 5 funding rounds, currently at the Acquired stage. Key investors include venBio, OrbiMed, Novartis Venture Fund, among 10 total investors. The company has 11-50 employees. Core technologies: Biologicals, Cells.

With $137M in total funding, ImmPACT Bio is a Acquired-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.

$137M
Raised
5
Rounds
10
Investors
3
Team
2017
Founded
1
Patents
Sector & Technology
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiologicalsCells
At a Glance
Investors

10 investors total

In the News

10 articles covered by sources including ir.lyell.com, www.globenewswire.com, www.biospace.com, www.prnewswire.com, www.finsmes.com.

ir.lyell.com · Oct 31, 2024
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
Read article ↗
Frequently Asked Questions
What does ImmPACT Bio do?

ImmPACT Bio is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have exhausted their treatment options. The company's logic-gate-based CAR T platforms address key biological challenges in treating cancer. ImmPACT Bio's technologies are specifically designed to prevent antigen escape, prevent "on-target off-tumor" toxicities, and overcome the immunosuppressive tumor microenvironment. The company's technology is based on the work of Yvonne Chen, PhD, and Antoni Ribas, MD, PhD, both from University of California, Los Angeles, and Gideon Gross, PhD, from the MIGAL-Galilee Research Institute.

How much funding has ImmPACT Bio raised?

ImmPACT Bio has raised $137M in total funding across 5 rounds. The company is currently at the Acquired stage. Key investors include venBio, OrbiMed, Novartis Venture Fund.

What sector is ImmPACT Bio in?

ImmPACT Bio operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

Where is ImmPACT Bio located?

ImmPACT Bio is based in Rehovot, Israel, Center District. The company also has offices abroad.

View Full Profile Classic View Website ↗